Lucid Diagnostics Inc.

Lucid Diagnostics Inc. (LUCD) received a notification from Nasdaq indicating its common stock has fallen below the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has 180 days, until April 12, 2027, to regain compliance by achieving a closing bid price of at least $1 for ten consecutive business days. While the notification does not immediately impact trading, Lucid Diagnostics intends to explore options to meet the listing standards.

Lucid Diagnostics Inc. reported its second quarter 2026 financial results, with EsoGuard revenue reaching $1.5 million and 2,770 EsoGuard tests processed. The company posted a GAAP net loss of $14.7 million, or $(0.08) per common share, and a non-GAAP adjusted loss of $10.9 million. Key business updates include securing a commercial coverage policy for EsoGuard from Concert and developing a health economic cost-effectiveness model to support payor engagement.

Lucid Diagnostics Inc. reported its second-quarter and six-month financial results for 2026, showing a significant increase in revenue but continued net losses. The company's management raised substantial doubt about its ability to continue as a going concern, citing ongoing losses and negative cash flows from operations. Revenue for the six months ended June 30, 2026, grew to $2.73 million, a 37.1% increase year-over-year, while the net loss attributable to common stockholders was $38.34 million. The company ended the period with $33.40 million in cash.

Lucid Diagnostics Inc. held its Annual Meeting of Stockholders on June 24, 2026, with approximately 84.7% of shares represented. Stockholders re-elected all management-nominated directors and approved an amendment to increase the total authorized common stock by 100,000,000 shares, raising the total to 400,000,000 shares. Additionally, the appointment of CBIZ CPAs P.C. as the independent registered certified public accounting firm for 2025 was ratified.

Lucid Diagnostics reported its first quarter 2026 financial results, with EsoGuard revenue reaching $1.3 million from 3,177 processed tests. The company posted a GAAP net loss of $23.6 million and a non-GAAP adjusted loss of $10.5 million. Lucid strengthened its balance sheet through a public offering, netting approximately $17 million, and ended the quarter with $45 million in proforma cash, extending its operational runway into 2027. The company continues to focus on securing Medicare coverage and expanding commercialization efforts for EsoGuard.

Lucid Diagnostics reported a significant increase in revenue and a narrower net loss for the first quarter of 2026. Revenue grew by 51.7% to $1.3 million, and the net loss attributable to common stockholders improved to $23.6 million from $36.0 million in the prior year period. Despite these improvements, the company continues to experience recurring losses and negative cash flows from operations, leading management to raise substantial doubt about its ability to continue as a going concern. Post-quarter, Lucid Diagnostics completed a registered direct offering, securing $16.8 million in net proceeds to support its operations.

Lucid Diagnostics Inc. announced its Annual Meeting of Stockholders to be held virtually on June 24, 2026. Stockholders will vote on the election of three Class B directors, a proposal to increase the authorized common stock by 100,000,000 shares to 400,000,000, and the ratification of CBIZ CPAs P.C. as the independent auditor for 2026. The Board unanimously recommends voting "FOR" all proposals, noting the authorized capital increase provides flexibility for future business needs but may have a dilutive effect on existing shareholders.

Lucid Diagnostics Inc. announced the closing of its previously announced underwritten public offering on April 24, 2026. The company successfully sold 18,000,000 shares of its common stock at a price of $1.00 per share. This offering is expected to generate approximately $16.8 million in net proceeds, which the company intends to allocate towards working capital and general corporate purposes.

Lucid Diagnostics Inc. has entered into an underwriting agreement with Canaccord Genuity LLC and BTIG, LLC for the sale of 18,000,000 shares of its common stock. This agreement outlines the terms for the offering and sale of these securities to the underwriters. The company has prepared and filed a registration statement on Form S-3 with the Securities and Exchange Commission for this transaction.